BMS on the prowl for deals

During Bristol-Myers Squibb's Q3 earnings call yesterday, CEO Jim Cornelius (photo) said the company has over $1.3 billion in its coffers to finance more deals with small drug developers. That's despite it's recent buyout of Medarex for $2.1 billion. The company will "continue to aggressively pursue acquisitions, licensing deals and other partnerships," promised Cornelius.

BMS could get an additional $1.7 billion when its former subsidiary Mead Johnson closes on some debt refinancing. Mead stock is up 77 percent since its IPO earlier this year.

- read the WSJ article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.